Is regorafenib a targeted drug? What is its mechanism of action?

Regorafenib is an oral multi-target tyrosine kinase inhibitor ( TKI), which is a targeted therapy drug. It was developed by the German company Bayer and was first approved by the U.S. Food and Drug Administration (FDA) in 2012. It is suitable for the treatment of various malignant tumors such as advanced colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC). The mechanism of action of regorafenib is different from traditional chemotherapy drugs. It mainly inhibits a variety of signaling pathways related to tumor growth, angiogenesis and tumor microenvironment, thereby preventing cancer cell proliferation and inhibiting the formation of tumor blood vessels.

The targets of regorafenib involve multiple key kinases, including vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), KIT, RET and RAF family, etc. These targets play important roles in tumor proliferation, angiogenesis, metastasis, and drug resistance. Through multi-target inhibition, regorafenib can effectively block the growth signals of tumor cells and reduce the supply of new blood vessels in tumors, leaving tumors in a state of nutritional deficiency and growth restriction, thereby achieving therapeutic effects.

In terms of clinical application, regorafenib has been widely used to treat patients with advanced or metastatic colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma (HCC) who have previously received sorafenib but have progressed. Clinical trials have shown that regorafenib can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients, providing a new treatment option for patients with advanced solid tumors. Especially in the field of liver cancer, regorafenib became the first approved second-line treatment drug after sorafenib, providing new hope for patients who are inoperable or target-resistant.

Reference materials:https://www.stivarga-us.com/